AGM Statement and Result of AGM

April 25, 2017

At the Company’s AGM held today the Chairman, Christopher Pearce, made the following statement: “As stated in our recent results, we expect 2017 to be a transformational year for Proteome Sciences.  The combination of strong revenue growth during 2016 and operational initiatives to simplify our strategy, consolidate our resources and broaden our commercial capability, have put the Company in a good position to take advantage of the increasing opportunities afforded by quantitative proteomics. Trading remains in line with management expectations.”  

Director Dealing and Total Voting Rights

April 20, 2017

Proteome Sciences plc (AIM:PRM) announces that on 7 April 2017, Ian Pike, Chief Scientific Officer of the Company and a former employee exercised 165,583 and 158,308 options over ordinary shares of 1p each in the capital of the Company (“Ordinary Shares”) respectively.

Option Awards

April 04, 2017

The Options represent 6.17% of the current issued share capital of the Company and lapse on 3 April 2027.

Appointment of Richard Dennis as Chief Commercial Officer

April 03, 2017

Richard Dennis commented: “I have been involved with proteins throughout my commercial career and am excited to be joining Proteome Sciences at this time. Never has the ‘power of the protein’ been better understood by, and more important to, the scientific community. Proteome Sciences can fully exploit this potential and I look forward to leading the commercial team to achieve this.”

Annual Report and Accounts 2016

March 31, 2017

Dr. Jeremy Haigh, Chief Executive remarks: "Enabling technologies such as ours afford us a tremendous opportunity… I am confident that we now have appropriate skills in the right locations pursuing a viable strategy for success. I look forward to further progress and substantial revenue growth in 2017."

Preliminary results for the year ended 31 December 2016 Notice of AGM

March 28, 2017

Jeremy Haigh, Chief Executive of Proteome Sciences, commented: “While we are satisfied with solid progress during 2016, there is clearly much yet to do if we want to realise the full commercial value of our proteomic technologies. The Company is in a transition phase as we seek to expand our customer base to secure larger and more durable contracts for our services. The recent decision to consolidate our laboratory facilities in Frankfurt was difficult given our UK heritage but we firmly believe it to be in the best interests of the Company and our shareholders. We look forward to healthy progress during 2017, to the imminent arrival of our new Chief Commercial Officer, and to providing further updates through the course of the year.”


Trading Update and Notice of Results

February 09, 2017

After a strong first half, progress continued throughout the rest of the year with results in line with expectations.  Buoyed by robust sales of our TMT® reagents and the associated royalties, unaudited revenues during the full year increased by 46%.

Holdings in Company and PDMR Shareholding

January 05, 2017

Proteome Sciences plc (AIM:PRM) received notification from Vulpes Life Sciences Fund, of which Martin Diggle, a non-executive director of the Company, is a director and partner, that today, it purchased 105,590 ordinary shares of 1 pence each at 5.5 pence per Ordinary Share.

Holdings in Company and PDMR Shareholding

January 04, 2017

Proteome Sciences plc (AIM:PRM) received notification from Vulpes Life Science Fund (“Vulpes”), of which Martin Diggle, a non-executive director of the Company, is a director and partner, that on 28, 29 and 30 December 2016, it purchased 265,000, 250,000 and 350,000 ordinary shares of 1 pence each (“Ordinary Shares”) respectively, at an average price of 5.74 pence per Ordinary Share (the “Transaction”).

Launch of New Website

December 19, 2016

Proteome Sciences is pleased to announce the launch of its newly designed corporate website, as anticipated in the Company’s interim results statement of 14 September 2016.